Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 11/20 | 0.54 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.52 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.52 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.52 |
| ▸ | PTK2 | Q05397 | 7/20 | 0.51 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.51 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.51 |
| ▸ | BRAF | P15056 | 1/20 | 0.50 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1504759 | 0.80 | IDH2 (0.44) | — | |
| SCHEMBL1504559 | 0.74 | MAPK14 (0.52) | MAPK14 | |
| SCHEMBL13741201 | 0.73 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL1504567 | 0.73 | L3MBTL1 (0.47) | — | |
| SCHEMBL12245421 | 0.73 | MAPK14 (0.88) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL1504498 | 0.72 | MAPK14 (0.79) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL3533400 | 0.71 | MAPK14 (0.95) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL13234638 | 0.71 | MAPK14 (0.72) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL18324914 | 0.71 | MAPK14 (1.00) | MAPK14MAPK13MAPK12MAPK11PTK2 | |
| SCHEMBL13234634 | 0.70 | MAPK14 (0.91) | MAPK14MAPK13MAPK12MAPK11PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173684-B2 | Pyridone derivatives as p38α MAPK inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-05-08 | — | — | US | disclosed |
| US-8173684-B2 | Pyridone derivatives as p38α MAPK inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-05-08 | — | — | US | disclosed |
| US-8173684-B2 | Pyridone derivatives as p38α MAPK inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-05-08 | — | — | US | disclosed |
| EP-2155683-B1 | PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS | ASTELLAS PHARMA INC (JP) | 2011-03-16 | — | — | EP | disclosed |
| US-20100063098-A1 | PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100063098-A1 | PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2010-03-11 | — | — | US | disclosed |
| US-20100063098-A1 | PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063098-A1 | PYRIDONE DERIVATIVES AS P38A MAPK INHIBITORS | MAPK1, MAPK6, MAPK3 | MAPK14 25/4885MAPK13 38/4885MAPK12 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.